title: Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.
abstract: Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis, but despite decades of research a safe and effective vaccine has remained elusive. The viral fusion glycoprotein (RSV F) plays an obligatory role in the entry process and is the major target of neutralizing antibodies, making it an attractive target for vaccine development. This review will summarize the recently determined structures of RSV F in the prefusion and postfusion conformations and describe the location and properties of neutralizing epitopes on RSV F, including the newly identified prefusion-specific epitopes. The influence of these findings on vaccine development will also be discussed, with a focus on the rational design and optimization of vaccine antigens.
authors.affiliation: Department of Biochemistry, Geisel School of Medicine at Dartmouth, 7200 Vail, Hanover, NH, 03755 USA. Electronic address: Jason.S.McLellan@Dartmouth.edu.
authors.forename: Jason S
authors.initials: JS
authors.lastname: McLellan
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D055808:Drug Discovery / Q000639:trends; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D011487:Protein Conformation; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology / Q000302:isolation & purification; D014760:Viral Fusion Proteins / Q000737:chemistry / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000939:Epitopes; C526850:F protein, human respiratory syncytial virus; D022261:Respiratory Syncytial Virus Vaccines; D014760:Viral Fusion Proteins
references.citation: J Virol. 2011 Aug;85(15):7788-96
references.pmid: 21613394
references.citation: Viruses. 2013 Feb 05;5(2):577-94
references.pmid: 23385470
references.citation: Pediatrics. 2013 Aug;132(2):e341-8
references.pmid: 23878043
references.citation: Curr Top Microbiol Immunol. 2013;372:39-57
references.pmid: 24362683
references.citation: J Virol. 2010 Aug;84(16):7970-82
references.pmid: 20534864
references.citation: J Mol Biol. 2007 May 4;368(3):652-65
references.pmid: 17362988
references.citation: J Gen Virol. 1993 Dec;74 ( Pt 12):2567-77
references.pmid: 7506298
references.citation: Am J Dis Child. 1986 Jun;140(6):543-6
references.pmid: 3706232
references.citation: Infect Disord Drug Targets. 2012 Apr;12(2):92-7
references.pmid: 22335498
references.citation: J Virol. 2011 Apr;85(8):3968-77
references.pmid: 21307202
references.citation: Virology. 2000 May 25;271(1):122-31
references.pmid: 10814577
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3089-94
references.pmid: 22323598
references.citation: J Mol Biol. 2011 Jun 24;409(5):853-66
references.pmid: 21549714
references.citation: Nat Med. 2010 Jan;16(1):123-8
references.pmid: 20023635
references.citation: J Virol. 2014 Oct;88(20):11802-10
references.pmid: 25078705
references.citation: J Infect Dis. 2012 Jul 1;206(1):56-62
references.pmid: 22529314
references.citation: J Infect Dis. 1997 Nov;176(5):1215-24
references.pmid: 9359721
references.citation: Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24
references.pmid: 21586636
references.citation: Nat Med. 2011 Aug 14;17(9):1132-5
references.pmid: 21841784
references.citation: Virus Res. 2011 Dec;162(1-2):80-99
references.pmid: 21963675
references.citation: Lancet. 2012 Dec 15;380(9859):2095-128
references.pmid: 23245604
references.citation: Curr Top Microbiol Immunol. 2013;372:83-104
references.pmid: 24362685
references.citation: Nature. 2014 Mar 13;507(7491):201-6
references.pmid: 24499818
references.citation: Curr Top Microbiol Immunol. 2013;372:155-71
references.pmid: 24362689
references.citation: Infect Disord Drug Targets. 2012 Apr;12(2):98-102
references.pmid: 22335500
references.citation: J Virol. 2010 Dec;84(23):12236-44
references.pmid: 20881049
references.citation: Pediatrics. 1998 Sep;102(3):531-7
references.pmid: 9724660
references.citation: J Gen Virol. 2007 Oct;88(Pt 10):2719-2723
references.pmid: 17872524
references.citation: J Infect Dis. 2015 Jan 15;211(2):216-25
references.pmid: 24864121
references.citation: Science. 2013 May 31;340(6136):1113-7
references.pmid: 23618766
references.citation: J Virol. 1998 Aug;72(8):6922-8
references.pmid: 9658147
references.citation: Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11133-8
references.pmid: 23776214
references.citation: Semin Immunol. 2013 Apr;25(2):160-71
references.pmid: 23778071
references.citation: J Virol. 1989 Jul;63(7):2941-50
references.pmid: 2470922
references.citation: Vaccine. 2014 Nov 12;32(48):6485-92
references.pmid: 25269094
references.citation: Virology. 2014 Jul;460-461:119-27
references.pmid: 25010277
references.citation: Nature. 2013 Sep 19;501(7467):439-43
references.pmid: 23955151
references.citation: Nat Struct Mol Biol. 2010 Feb;17(2):248-50
references.pmid: 20098425
references.citation: Vaccine. 2013 Apr 18;31 Suppl 2:B209-15
references.pmid: 23598484
references.citation: Virology. 2010 Jan 20;396(2):226-37
references.pmid: 19922971
references.citation: Science. 2013 Nov 1;342(6158):592-8
references.pmid: 24179220
references.citation: J Gen Virol. 1992 Sep;73 ( Pt 9):2225-34
references.pmid: 1383404